246 related articles for article (PubMed ID: 37773823)
1. Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.
Yan Z; Xu Y; Li K; Liu L
Medicine (Baltimore); 2023 Sep; 102(39):e34690. PubMed ID: 37773823
[TBL] [Abstract][Full Text] [Related]
2. Mendelian randomization analyses identified bioavailable testosterone mediates the effect of sex hormone-binding globulin on prostate cancer.
Wan B; Lu L; Lv C
Andrology; 2023 Sep; 11(6):1023-1030. PubMed ID: 36524281
[TBL] [Abstract][Full Text] [Related]
3. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
4. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
5. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
[TBL] [Abstract][Full Text] [Related]
6. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
[TBL] [Abstract][Full Text] [Related]
7. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
8. Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study.
Ma L; Du Y; Ma C; Liu M
Front Endocrinol (Lausanne); 2023; 14():1272167. PubMed ID: 38047111
[TBL] [Abstract][Full Text] [Related]
9. Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.
Yan Z; Xu Y; Li K; Liu L
Acta Neurol Belg; 2024 Apr; 124(2):485-494. PubMed ID: 37889424
[TBL] [Abstract][Full Text] [Related]
10. New evidence for the effect of type 2 diabetes and glycemic traits on testosterone levels: a two-sample Mendelian randomization study.
Jiang C; Wang Y; Yang W; Yang X
Front Endocrinol (Lausanne); 2023; 14():1238090. PubMed ID: 37900148
[TBL] [Abstract][Full Text] [Related]
11. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD
J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315
[TBL] [Abstract][Full Text] [Related]
12. Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Orho-Melander M; Hindy G; Borgquist S; Schulz CA; Manjer J; Melander O; Stocks T
Int J Epidemiol; 2018 Apr; 47(2):495-505. PubMed ID: 29165714
[TBL] [Abstract][Full Text] [Related]
13. A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Liu G; Shi M; Mosley JD; Weng C; Zhang Y; Lee MTM; Jarvik GP; Hakonarson H; Namjou-Khales B; Sleiman P; Luo Y; Mentch F; Denny JC; Linton MF; Wei WQ; Stein CM; Feng Q
JAMA Netw Open; 2021 Jun; 4(6):e2112820. PubMed ID: 34097045
[TBL] [Abstract][Full Text] [Related]
14. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
15. Mendelian Randomization Study of
Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
[TBL] [Abstract][Full Text] [Related]
16. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
17. Blood lipids and prostate cancer: a Mendelian randomization analysis.
Bull CJ; Bonilla C; Holly JM; Perks CM; Davies N; Haycock P; Yu OH; Richards JB; Eeles R; Easton D; Kote-Jarai Z; Amin Al Olama A; Benlloch S; Muir K; Giles GG; MacInnis RJ; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pashayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park J; Kaneva R; Batra J; Teixeira MR; Micheal A; Pandha H; Smith GD; Lewis SJ; Martin RM;
Cancer Med; 2016 Jun; 5(6):1125-36. PubMed ID: 26992435
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.
Li Z; Tian M; Jia H; Li X; Liu Q; Zhou X; Li R; Dong H; Liu Y
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):197-206. PubMed ID: 37688479
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
20. Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.
Sun X; Ping J; Guo X; Long J; Cai Q; Shu XO; Shu X
Mol Carcinog; 2024 May; 63(5):849-858. PubMed ID: 38517045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
